- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Wockhardt's Chikalthana plant gets GMP certificate from UKMHRA
New Delhi: In a major relief to drug firm Wockhardt, its Chikalthana plant at Aurangabad in Maharashtra has received a good manufacturing practice (GMP) certificate from the UK health regulator after an inspection.
"The company has undergone recently an inspection at its L1-Chikalthana, Aurangabad manufacturing facility by UK MHRA and has received a communication confirming the closure of the inspection and issuance of an unrestricted GMP certificate", Wockhardt said in a filing to BSE.
In a filing to the bourses in October this year, Wockhardt had said United Kingdom Medicines and Healthcare Products Regulatory Agency (UKMHRA) had completed inspection of its Chikalthana plant without issuing any critical observations on the facility.
The UK regulator had in October 2013 withdrawn the GMP certificate to the Chikalthana plant and had also initiated recall of five prescription medicines from there.
"The company has undergone recently an inspection at its L1-Chikalthana, Aurangabad manufacturing facility by UK MHRA and has received a communication confirming the closure of the inspection and issuance of an unrestricted GMP certificate", Wockhardt said in a filing to BSE.
In a filing to the bourses in October this year, Wockhardt had said United Kingdom Medicines and Healthcare Products Regulatory Agency (UKMHRA) had completed inspection of its Chikalthana plant without issuing any critical observations on the facility.
The UK regulator had in October 2013 withdrawn the GMP certificate to the Chikalthana plant and had also initiated recall of five prescription medicines from there.
Next Story